DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

906 D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular
risk profile for use in primary care: The
Framingham Heart Study. Circulation, 2008, 117:743–753.
Daniels SR, Greer FR, and the Committee on Nutrition. Lipid
screening and cardiovascular health in childhood. Pediatrics,
2008, 122:198–208.
Davis HR Jr, Altmann SW. Niemann–Pick C1 Like 1 (NPC1L1)
an intestinal sterol transporter. Biochim Biophys Acta, 2009,
1791:679–683.
Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a
potent cholesterol absorption inhibitor, inhibits the development
of atherosclerosis in apoE knockout mice. Arterioscler
Thromb Vasc Biol, 2001a, 21:2032–2038.
Davis HR Jr, Pula KK, Alton KB, et al. The synergistic hypercholesterolemic
activity of the potent cholesterol absorption
inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors in dogs. Metabolism,
2001b, 50:1234–1241.
Davis HR Jr, Zhu L-J, Hoos LM, et al. Niemann-Pick C1 Like 1
(NPC1L1) is the intestinal phytosterol and cholesterol transporter
and a key modulator of whole-body cholesterol homeostasis.
J Biol Chem, 2004, 279:33586–33592.
deGoma EM, deGoma RL, Rader DJ. Beyond high-density
lipoprotein cholesterol levels: Evaluating high-density lipoprotein
function as influenced by novel therapeutic approaches.
J Am Coll Cardiol, 2008, 51:2199–2211.
Diamond GA, Kaul S. Prevention and treatment: A tale of two
strategies. J Am Coll Cardiol, 2008, 51:46–48.
Ebrahimi R, Saleh J, Toggart E, et al. Effect of preprocedural
statin use on procedural myocardial infarction and major cardiac
adverse events in percutaneous coronary intervention: A
meta-analysis. J Invasive Cardiol, 2008, 20:292–295.
Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk
patients with ezetimibe plus simvastatin co-administration versus
simvastatin alone to attain National Cholesterol Education
Program Adult Treatment Panel III low-density lipoprotein
cholesterol goals. Am J Cardiol, 2004, 93:1481–1486.
Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment
of incremental coronary risk prediction using C-reactive protein
and other novel risk markers: The Atherosclerosis Risk in
Communities Study. Arch Intern Med, 2006, 166:1368–1373.
Franz HM, Lionel P, Simon SKT, et al. Impact of systemic
hypertension on the cardiovascular benefits of statin therapy—
A meta-analysis. Am J Cardiol, 2008, 101:319–325.
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primaryprevention
trial with gemfibrozil in middle-aged men with dyslipidemia.
Safety of treatment, changes in risk factors, and
incidence of coronary heart disease. N Engl J Med, 1987,
317:1237–1245.
Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe
added to ongoing statin therapy for treatment of
patients with primary hypercholesterolemia. Am J Cardiol,
2002, 90:1084–1091.
Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively
inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
J Lipid Res, 2004, 45:1835–1845.
Ginsberg HN, Bonds DE, Lovato LC, et al. Evolution of the lipid
trial protocol of the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial. Am J Cardiol, 2007, 99(suppl):
56i–67i.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial
of rosuvastatin in the prevention of venous thromboembolism.
N Engl J Med, 2009, 360:1851–1861.
Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic
syndrome. Report of the National Heart, Lung, and Blood
Institute/American Heart Association conference on scientific
issues related to definition. Circulation, 2004a, 109:433–438.
Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent
clinical trials for the National Cholesterol Education Program
Adult Treatment Panel III guidelines. Circulation, 2004b,
110:227–239.
Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and
tolerability of once-daily niacin for the treatment of dyslipidemia
associated with type 2 diabetes: Results of the assessment
of diabetes control and evaluation of the efficacy of
niaspan trial. Arch Intern Med, 2002, 162:1568–1576.
Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability
of simvastatin plus fenofibrate for combined hyperlipidemia
(the SAFARI trial). Am J Cardiol, 2005, 95:462–468.
Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride
levels and long-term mortality in patients with coronary
heart disease. The Bezafibrate Infarction Prevention (BIP) registry.
Circulation, 1999, 100:475–482.
Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol
trial: Clarifications. Lancet, 1992, 340:1405–1406.
Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in 20
536 high-risk individuals: A randomised placebo-controlled
trial. Lancet, 2002, 360:7–22.
Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol-lowering with simvastatin in
5963 people with diabetes: A randomised placebo-controlled
trial. Lancet, 2003, 361:2005–2016.
Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: Its
role in LDL metabolism. Trends Biochem Sci, 2007, 32:71–77.
Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin
improves the atherogenic and atheroprotective lipid profiles in
patients with hypertriglyceridemia. Coron Artery Dis, 2004,
15:115–123.
Hussain MM, Bakillah A. New approaches to target microsomal
triglyceride transfer protein. Curr Opin Lipidol, 2008, 19:572–578.
Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an
uptake transporter) and ABCG2 (BCRP, an efflux transporter)
variant alleles and pharmacokinetics of pitavastatin in healthy
volunteers. Clin Pharmacol Ther, 2007, 82:541–547.
Jafri H, Alsheikh-Ali AA, Karas RH. Abstract 1423: Statin therapy
does not reduce the increased cardiovascular risk associated
with low levels of high-density lipoprotein cholesterol:
Evidence from randomized controlled trials. Circulation,
2009, 120:S500.
Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose
efficacy study of atorvastatin versus simvastatin, pravastatin,
lovastatin, and fluvastatin in patients with hypercholesterolemia
(the CURVES study). Am J Cardiol, 1998, 81:582–587.
Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety
of fenofibric acid in combination with a statin in patients with
mixed dyslipidemia: Pooled analysis of three phase 3, 12-week
randomized, controlled studies. J Clin Lipidol, 2009, 3:125–137.
Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy
and safety of rosuvastatin versus atorvastatin, simvastatin,